Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma patients. Isatuximab (10 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Usmani, Saad Z., Karanes, Chatchada, Bensinger, William I., D’Souza, Anita, Raje, Noopur, Tuchman, Sascha A., Sborov, Douglas, Laubach, Jacob P., Bianchi, Giada, Kanagavel, Dheepak, Saleem, Rao, Dubin, Franck, Campana, Frank, Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632673/
https://www.ncbi.nlm.nih.gov/pubmed/34050260
http://dx.doi.org/10.1038/s41375-021-01262-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632673/
https://www.ncbi.nlm.nih.gov/pubmed/34050260
http://dx.doi.org/10.1038/s41375-021-01262-w

Ejemplares similares